New Peer Review Article Entitled “Efficacy and safety of fexapotide triflutate in outpatient medical treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia” Published in Therapeutic Advances in Urology
January 15, 2019 10:45 ET
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., Jan. 15, 2019 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) reports today that a new peer review article has been published in Therapeutic Advances in...
2018: A Year of Achievements for NYMOX
December 19, 2018 10:30 ET
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., Dec. 19, 2018 (GLOBE NEWSWIRE) -- Following the Nymox (NASDAQ: NYMX) Annual General Meeting yesterday (December 18, 2018), Nymox management discussed many significant 2018...
Corporate Update To Shareholders: Preparatory Work For Regulatory Filings On Track
October 11, 2018 10:45 ET
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Following many shareholder enquiries in recent weeks Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to provide shareholders...
Nymox Reports 78 Month Results From Biopsy and Surgery Confirmed Prospective Randomized NX03-0040 Prostate Cancer Study of Fexapotide Triflutate: Gleason Grade Progression Reduced by 81% Overall and Fexapotide 15mg Minimal Treatment Leads to 73% Long-Term Reduction in Incidence of Associated Prostate Cancer Surgery and Radiotherapy
October 09, 2018 10:00 ET
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce today important new long-term clinical trial results from the...
Nymox Reports Safety Benefits of Fexapotide Treatments for Prostate Cancer and Benign Prostatic Hyperplasia
October 03, 2018 11:46 ET
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) reported today that after long-term safety assessments of repeated Fexapotide Triflutate...
NYMOX Announces Expanded Marketing Plans
July 02, 2018 09:30 ET
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., July 02, 2018 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) announced today that following the recently announced increased manufacturing capabilities,...
NYMOX Successfully Achieves Manufacturing Scale-Up
June 07, 2018 09:30 ET
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., June 07, 2018 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to report that manufacturing scale-up milestones have been reached for the...
Fexapotide Triflutate Pivotal Phase 3 Study Results Presented and Discussed at American Urological Association Annual Meeting in San Francisco
May 22, 2018 10:00 ET
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., May 22, 2018 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to report on a successful symposium discussing Nymox’s lead product candidate...
Nymox’s Fexapotide Featured in Broadcast of Grand Rounds in Urology
May 11, 2018 09:30 ET
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., May 11, 2018 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce that an informative interview and presentation was released on Grand...
Nymox Announces Relocation of Company Headquarters to Switzerland
May 07, 2018 09:00 ET
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., May 07, 2018 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce that it has initiated the process of relocating the Company...